Nature Communications (Apr 2018)
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
- Michael R. McDevitt,
- Daniel L. J. Thorek,
- Takeshi Hashimoto,
- Tatsuo Gondo,
- Darren R. Veach,
- Sai Kiran Sharma,
- Teja Muralidhar Kalidindi,
- Diane S. Abou,
- Philip A. Watson,
- Bradley J. Beattie,
- Oskar Vilhemsson Timmermand,
- Sven-Erik Strand,
- Jason S. Lewis,
- Peter T. Scardino,
- Howard I. Scher,
- Hans Lilja,
- Steven M. Larson,
- David Ulmert
Affiliations
- Michael R. McDevitt
- Department of Radiology, Memorial Sloan Kettering Cancer Center
- Daniel L. J. Thorek
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine
- Takeshi Hashimoto
- Department of Urology, Tokyo Medical University
- Tatsuo Gondo
- Department of Urology, Tokyo Medical University
- Darren R. Veach
- Department of Radiology, Memorial Sloan Kettering Cancer Center
- Sai Kiran Sharma
- Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan Kettering Cancer Center
- Teja Muralidhar Kalidindi
- Department of Radiology, Memorial Sloan Kettering Cancer Center
- Diane S. Abou
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine
- Philip A. Watson
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Bradley J. Beattie
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center
- Oskar Vilhemsson Timmermand
- Division of Oncology, Clinical Sciences, Lund University and Skåne University Hospital
- Sven-Erik Strand
- Department of Clinical Sciences, Medical Radiation Physics, Lund University
- Jason S. Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center
- Peter T. Scardino
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
- Howard I. Scher
- Department of Urology, Weill Cornell Medical College
- Hans Lilja
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
- Steven M. Larson
- Department of Radiology, Memorial Sloan Kettering Cancer Center
- David Ulmert
- Division of Oncology, Clinical Sciences, Lund University and Skåne University Hospital
- DOI
- https://doi.org/10.1038/s41467-018-04107-w
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
Radionuclides that emit alpha particles (charged helium nuclei) are currently used clinically to treat cancers including prostate cancer. Here, the authors combine a humanized antibody to an alpha particle emitter, specifically to target a downstream effector of the androgen receptor and create a feed forward loop that increases the therapeutic efficacy.
